Weight gain is one of the most commonly reported concerns among people starting Biktarvy. It is real, it is documented in clinical trials, and it affects some patients more than others. But the picture is more nuanced than a simple warning: some weight gain in the early months reflects recovery, not harm, while longer-term gain in some individuals carries genuine metabolic risk. This page reviews what the evidence says, who is most affected, and what options are available when weight gain becomes a problem.
Does Biktarvy Cause Weight Gain?
Yes — weight gain is a recognised and documented side effect of Biktarvy. It is not unique to Biktarvy specifically; it is a class effect shared by all integrase strand transfer inhibitors (INSTIs), which includes bictegravir (the “B” in Biktarvy), dolutegravir (Tivicay, Dovato), and cabotegravir (Cabenuva). Multiple large randomised trials and real-world cohort studies have confirmed that INSTI-based regimens produce more weight gain than efavirenz-based or protease inhibitor-based regimens.
The Biktarvy-specific phase 3 trials — GS-US-380-1489 and GS-US-380-1490 — reported mean weight gains of approximately 2 kg (4.4 lbs) at 48 weeks and approximately 4 kg (8.8 lbs) at 96 weeks in treatment-naive patients. These figures reflect averages across all participants; individual variation is considerable.
Important context: Average weight gain figures in clinical trials include patients whose gain is partly or wholly explained by immune reconstitution — the body recovering healthy tissue mass after viral suppression. This is not a harmful drug effect. The concern is with excess weight gain beyond this recovery, particularly when it continues past the first year.
How Much Weight Gain Is Typical on Biktarvy?
Reported weight gain varies considerably depending on the patient population, prior treatment history, and how long patients have been on the drug:
- Treatment-naive patients: Mean gain of 2–4 kg over the first 48 weeks, reaching 4–6 kg by 96–144 weeks in some cohorts. The most significant gain typically occurs in the first 6–12 months.
- Patients switching from a TDF-based regimen to Biktarvy (TAF-based): An additional 2–4 kg above baseline weight at the time of switch, occurring over 12–24 months.
- Patients switching from an efavirenz-based regimen: Higher weight gain, sometimes 5–8 kg, because efavirenz actively suppresses weight.
- Women and people of Black African descent: Consistently higher weight gain in these groups across all INSTI-based regimens; some analyses report 2–3× the gain seen in white male patients.
Roughly 20–25% of patients in some long-term cohorts gain 10% or more of their baseline body weight — the threshold most clinicians consider clinically significant from a metabolic risk perspective.
Why Biktarvy Causes More Weight Gain Than Older Regimens
-
1
INSTI-specific CNS effects on energy regulation. Integrase inhibitors appear to affect hypothalamic appetite and energy expenditure pathways. Animal models have demonstrated that INSTIs can reduce resting energy expenditure and alter fat distribution independently of viral suppression, thought to involve effects on melanocortin signalling.
-
2
TAF versus TDF component effect. Tenofovir disoproxil fumarate (TDF) caused mild tubular toxicity in the kidneys, which had the unintended side effect of suppressing weight. Tenofovir alafenamide (TAF), used in Biktarvy, is safer for kidneys and bones — but removing TDF’s weight-suppressive toxicity means patients who switch from TDF to TAF often gain weight that was previously being artificially held down.
-
3
Immune reconstitution and return to health. When HIV replication is suppressed, the body is no longer in a chronic inflammatory, catabolic state. This drives healthy weight restoration in the first 6–12 months. This component of early weight gain is beneficial and expected — it is not drug toxicity.
Who Is Most Likely to Gain Weight on Biktarvy?
- Female sex: Women gain more weight than men on INSTI-based regimens on average, with some studies reporting approximately twice the gain over 96 weeks.
- Black African or African American ethnicity: Higher rates of significant weight gain across multiple large trials; the mechanism is not fully understood but is consistently reported.
- Low baseline CD4 count: Patients starting treatment with a lower CD4 count have more immune reconstitution to undergo, and therefore more early weight gain from return-to-health effects.
- Switching from efavirenz or TDF-based regimens: Removing active weight suppression from prior drugs accelerates weight gain after the switch.
- Pre-existing overweight or obesity: Some data suggest higher absolute weight gain in those already overweight at baseline.
If you are in a higher-risk group: This does not mean you should avoid Biktarvy. It does mean that baseline weight, BMI, lipids, and fasting glucose should be documented before starting, and monitored at 3, 6, and 12 months.
Is It Weight Gain or Return to Health?
Weight gain in the first 3–6 months of starting antiretroviral therapy in a treatment-naive patient with a low CD4 count is often predominantly return-to-health weight. The pattern that warrants clinical attention is:
- Continued weight gain beyond 12 months of treatment
- Gain predominantly in visceral/abdominal fat rather than lean mass
- Weight gain accompanied by worsening lipids (LDL, triglycerides) or rising fasting glucose
- Gain in patients who were already at a healthy weight or overweight before starting treatment
- Significant gain in patients switching regimens who already had immune reconstitution on prior therapy
Biktarvy Weight Gain Compared to Other HIV Medications
| Regimen | Drug Class | Weight Gain Profile | Relative Risk |
|---|---|---|---|
| Biktarvy (BIC/FTC/TAF) | INSTI + TAF | ~2–4 kg at 48 wks; ~4–6 kg at 96 wks (treatment-naive) | Moderate |
| Dovato (DTG/3TC) | INSTI + NRTI | Comparable to Biktarvy; no TAF component reduces some weight gain risk | Moderate |
| Cabenuva (CAB/RPV) | INSTI + NNRTI (injectable) | Similar INSTI-driven weight gain; long-acting monthly/bimonthly dosing | Moderate |
| Triumeq (DTG/ABC/3TC) | INSTI + NRTIs (no TAF) | INSTI-driven gain; lower than Biktarvy due to absence of TAF effect | Moderate–Low |
| Atripla / EFV-based | NNRTI (efavirenz) | Lower or neutral weight gain; EFV actively suppresses weight | Lower |
| Pifeltro (doravirine-based) | NNRTI (doravirine) | Significantly less weight gain than INSTIs in comparative studies | Lower |
| TDF-based regimens | TDF backbone (older) | Lower weight gain due to TDF-specific weight-suppressive effect | Lower |
Switching to reduce weight gain carries trade-offs. Efavirenz has well-documented CNS side effects (vivid dreams, dizziness, mood changes) that many patients find intolerable. TDF is associated with kidney and bone density risks. Any regimen switch to address weight must be evaluated against the reasons Biktarvy was chosen in the first place — high barrier to resistance, tolerability, and once-daily dosing.
What You Can Do About Weight Gain on Biktarvy
Lifestyle Modifications
- Aerobic and resistance exercise: Both are important. Current guidance recommends at least 150 minutes of moderate-intensity aerobic activity per week. Resistance training helps preserve lean mass and improve insulin sensitivity.
- Dietary adjustment: A Mediterranean-style diet — high in vegetables, legumes, whole grains, fish, and olive oil — has the strongest evidence base for reducing cardiovascular risk in people living with HIV.
- Limit ultra-processed food and alcohol: Both are associated with adipose tissue gain independent of HIV treatment effects.
Medical and Pharmacological Options
- Metabolic monitoring: Annual fasting lipids, glucose, HbA1c, and blood pressure allow early detection of metabolic consequences before they progress.
- GLP-1 receptor agonists (semaglutide, liraglutide): No contraindication with Biktarvy; increasingly used in people living with HIV for weight management and cardiovascular risk reduction.
- Statin therapy: For patients with worsening lipid profiles, statins are appropriate but require dose capping alongside Biktarvy — see the drug interactions guide for specifics.
Regimen Switch Discussion
For patients with significant, persistent weight gain causing metabolic complications, switching the antiretroviral regimen is a legitimate option. Regimens that have shown less weight gain include doravirine-based combinations (e.g., Delstrigo) and certain protease inhibitor-based regimens. Any switch must be evaluated by your HIV specialist against your resistance history, tolerability, and viral suppression goals.
Do not stop Biktarvy without guidance. Abruptly discontinuing any antiretroviral regimen carries the risk of viral rebound and potentially resistance development. If weight is a concern, bring it to your clinic — there are options to manage it without compromising your HIV control.
For context on how Biktarvy compares to Dovato across multiple dimensions including weight, see our Dovato vs Biktarvy comparison guide. For a full overview of Biktarvy side effects beyond weight, see the Biktarvy long-term side effects page.
Frequently Asked Questions
No. While weight gain is a documented and common effect of Biktarvy and other integrase inhibitor-based regimens, not every patient experiences it to a clinically meaningful degree. Some patients gain very little, some gain none, and a small number lose weight — particularly if they were already overweight and improve their diet and exercise habits after starting treatment.
Phase 3 trial data report a mean weight gain of approximately 2 kg (4.4 lbs) at 48 weeks and approximately 4 kg (8.8 lbs) at 96 weeks in treatment-naive patients. Individual outcomes range from no gain to 10 kg or more, with women and patients of Black African descent consistently showing higher-than-average gains. Patients switching from a TDF-based regimen tend to gain an additional 2–4 kg above their switch weight over the following 12–24 months.
No — weight gain on Biktarvy is not a sign that the drug is failing. In fact, weight gain in the first months of treatment in a previously untreated patient often indicates that the drug is working well: the immune system is recovering and the body is restoring healthy tissue mass. Viral load and CD4 count results, not body weight, are the measures of whether Biktarvy is controlling HIV effectively.
Yes, and this is a well-documented switch effect. Tenofovir disoproxil fumarate (TDF) suppresses weight via mild tubular toxicity in the kidneys. Tenofovir alafenamide (TAF), used in Biktarvy, was developed specifically to be safer for kidneys and bones. Removing TDF’s weight-suppressive effect causes many patients who switch to TAF-based regimens to gain 2–4 kg over the following year.
Not without a thorough discussion with your HIV specialist. Regimen switches to address weight are legitimate when weight gain is causing metabolic complications that cannot be managed by lifestyle modification alone. However, every regimen switch carries trade-offs. Your HIV specialist needs to evaluate whether the benefits of switching outweigh the risks in your specific case.
Yes, modest metabolic changes have been observed in clinical trials and real-world cohorts. Some patients show increases in total cholesterol, LDL cholesterol, and triglycerides compared to TDF-based regimens — partly because TDF suppressed lipids via the same kidney-mediated mechanism that suppressed weight, and partly due to the integrase inhibitor component. Annual fasting lipids and glucose are standard of care for people on Biktarvy.
This article was reviewed by Dr. Neha Mishra, MD, and written by Karen Cooksey in accordance with SunnyPharma’s Editorial Policy. Content is reviewed for clinical accuracy, updated when guidelines change, and written to inform — not replace — the advice of a qualified healthcare provider.
References
- Sax PE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389.
- Venter WDF, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV (ADVANCE): 96-week results. Lancet HIV. 2020;7(10):e666–e676.
- Gilead Sciences. Biktarvy US Prescribing Information (GS-US-380-1489 and GS-US-380-1490 trial data). January 2024.
- Lake JE, et al. The metabolic effects of modern antiretroviral therapy. Expert Rev Clin Pharmacol. 2021;14(5):567–582.
- DHHS Panel on Antiretroviral Guidelines. Weight Gain with Antiretroviral Therapy. Updated January 2025. clinicalinfo.hiv.gov
- Bourgi K, et al. Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to NNRTIs or PIs. J Acquir Immune Defic Syndr. 2020;83(2):185–191.